LI
NBIX icon

LMCG Investments’s Neurocrine Biosciences NBIX Stock Holding History

LMCG Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-6,771
Closed -$932K – 263
2024
Q2 		$932K Sell
6,771
-31
-0.5% -$4.25K 0.05% 195
2024
Q1 		$938K Sell
6,802
-2,625
-28% -$358K 0.06% 207
2023
Q4 		$1.24M Hold
9,427
– – 0.08% 204
2023
Q3 		$1.06M Buy
9,427
+193
+2% +$20.3K 0.07% 202
2023
Q2 		$871K Hold
9,234
– – 0.06% 224
2023
Q1 		$935K Buy
9,234
+198
+2% +$20.6K 0.06% 213
2022
Q4 		$1.08M Buy
9,036
+17
+0.2% +$1.99K 0.08% 206
2022
Q3 		$958K Buy
9,019
+11
+0.1% +$1.12K 0.07% 226
2022
Q2 		$878K Hold
9,008
– – 0.06% 232
2022
Q1 		$845K Buy
+9,008
New +$763K 0.05% 242
2015
Q3 		$6.77M Buy
170,154
+23,470
+16% +$1.13M 0.15% 263
2015
Q2 		$7M Buy
146,684
+3,149
+2% +$134K 0.15% 262
2015
Q1 		$5.7M Buy
+143,535
New +$5.13M 0.12% 291

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

LMCG Investments's NBIX Position: Q3 2024 in Review

LMCG Investments sold out of Neurocrine Biosciences (NBIX) in Q3 2024, closing a stake of 6,771 shares — an estimated $932K sold.

LMCG Investments first reported a position in NBIX in Q1 2015 and held it in 13 quarters. The position peaked at $7M in Q2 2015. 574 funds tracked by Wall St. Rank hold NBIX as of Q3 2024.

  • LMCG Investments reported no remaining Neurocrine Biosciences position as of Q3 2024 after selling out during the quarter.
  • LMCG Investments sold 6,771 Neurocrine Biosciences shares in Q3 2024, an estimated $932K.
  • LMCG Investments first reported a position in Neurocrine Biosciences in Q1 2015 and held it in 13 quarters.
  • LMCG Investments's Neurocrine Biosciences position peaked at $7M in Q2 2015.
  • 574 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2024.

Based on LMCG Investments's 13F filing for Q3 2024, filed 29 Oct 2024.